ArticleCancer management and research2019
Prognostic value of lactate dehydrogenase to albumin ratio (LAR) in patients with resectable esophageal squamous cell carcinoma.
Article in Cancer management and research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 39 citations in OpenAlex.
- Prognostic value of the preoperative lactate dehydrogenase-to-albumin ratio in patients with gastrointestinal cancer.Oncology letters · 2026Article
- Preoperative lactate dehydrogenase-to-albumin ratio as a nutrition-inflammation index associated with postoperative pneumonia after McKeown esophagectomy: a retrospective cohort study.Frontiers in nutrition · 2026Article
- Definitive chemoradiotherapy plus immune checkpoint inhibitors for locally advanced unresectable esophageal squamous cell carcinoma: survival and progression patterns in a propensity-matched cohort.Frontiers in immunology · 2026Article
- Preoperative Lactate Dehydrogenase-to-Albumin Ratio and Overall Survival in Gastric Cancer: Stage-Specific Prognostic Implications.Cancer management and research · 2026Article
- Serum lactate Dehydrogenase-to-Albumin ratio in upper tract urothelial carcinoma: A promising prognostic biomarker.BMC urology · 2025Article
- Article
- Can pretreatment lactate dehydrogenase to albumin ratio predict pathological complete response after neoadjuvant chemotherapy in breast cancer patients?Journal of medical biochemistry · 2025Article
- Prognostic significance of the preoperative lactate dehydrogenase-to-albumin ratio in patients undergoing radical resection for hilar cholangiocarcinoma.Frontiers in medicine · 2025Article
- Prognostic value of the lactate dehydrogenase to albumin ratio in cancer patients.Frontiers in nutrition · 2025Article
- Association Between Lactate Dehydrogenase/Albumin Ratio and in-Hospital Mortality in Patients with Acute Aortic Dissection.Journal of inflammation research · 2025Article
- Prognostic value of the lactate dehydrogenase to albumin ratio in advanced non-small cell lung cancer patients treated with the first-line PD-1 checkpoint inhibitors combined with chemotherapy.Frontiers in immunology · 2025Article
- Does the LDH/Albumin Ratio Bring Novelty? A Comparative Analysis with Inflammatory Indices and Combined Models in Adult-Onset Still's Disease.Diagnostics (Basel, Switzerland) · 2024Article
- Association between lactate dehydrogenase to albumin ratio and acute kidney injury in patients with sepsis: a retrospective cohort study.Clinical and experimental nephrology · 2024Article
- Indices and ferritin level that predict organ involvement in adult-onset Still's disease.Biomarkers in medicine · 2024Article
- Effect of Preoperative Serum Lactate Dehydrogenase-to-Albumin Ratio on the Survival of Oral Cancer: A Retrospective Study.Journal of inflammation research · 2024Article
- Biomarkers of lymph node metastasis in esophageal cancer.Frontiers in immunology · 2024Review
- Lactate dehydrogenase to albumin ratio (LAR) is a novel predictor of fatal outcome in patients with SFTS: an observational study.Frontiers in public health · 2024Observational
- Is High Score of Preoperative Lactate Dehydrogenase to Albumin Ratio Predicting Poor Survivals in Esophageal Carcinoma Patients?Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia · 2023Article
- Article
- Prognostic implication of lactic dehydrogenase-to-albumin ratio in critically ill patients with acute kidney injury.Clinical and experimental nephrology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWe firstly identified a combination of lactate dehydrogenase (LDH) along with albumin (ALB), which was defined as LAR (LDH/ALB ratio). The purpose of our study here was initially to explore the prognostic role of LAR in patients with esophageal squamous cell carcinoma (ESCC) undergoing esophagectomy. PATIENTS AND
methodsA retrospective study was conducted including 346 resectable ESCC patients. Patients who received curative surgery without any neoadjuvant therapy were included in the current study. The X-tile program was performed to calculate the optimal cut-off values for LDH, ALB and LAR. The Kaplan-Meier methods, Cox regression univariate and multivariate analyses were utilized to analyze the prognostic factors for cancer-specific survival (CSS).
resultsThere were 76 (22.0%) women and 270 (78.0%) men in all 346 patients. The mean value for serum LDH, ALB and LAR were 180±62 U/L (range 28-473 U/L), 40.3±5.3 g/L (range 26.6-52.4 g/L) and 4.6±1.8 (range 0.64-14.97), respectively. According to the X-tile program, the optimum cut-off points were 220 (U/L), 40.5 (g/L), and 5.5 for LDH, ALB, and LAR, respectively. The 5-year CSS was 31.8%. Patients with a high level of LAR (>5.5) were associated with poor CSS (13.3% vs 38.3%,
conclusionOur retrospective observations indicate that LAR is a useful potential prognostic biomarker in resectable ESCC patients who received curative surgery without any neoadjuvant therapy with the optimal cut-off value of 5.5.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.